196 related articles for article (PubMed ID: 32812063)
1. Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains.
Zhao W; Kong L; Wu C; Wu X
Eur J Clin Pharmacol; 2021 Jan; 77(1):79-86. PubMed ID: 32812063
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
Wu X; Tang Y; Zhang X; Wu C; Kong L
Drug Des Devel Ther; 2018; 12():1679-1684. PubMed ID: 29928111
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic analysis of meropenem, by Monte Carlo simulation, in both plasma and cerebrospinal fluid in patients with cerebral hemorrhage after external ventricular drainage
.
Kong L; Xu H; Wu C; Kong X; Yu M; Shi Q; Wu X
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):50-56. PubMed ID: 31670654
[TBL] [Abstract][Full Text] [Related]
4. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.
Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A
Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965
[TBL] [Abstract][Full Text] [Related]
5. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
Viaggi B; Paolo AD; Danesi R; Polillo M; Ciofi L; Del Tacca M; Malacarne P
Scand J Infect Dis; 2011 Sep; 43(9):721-7. PubMed ID: 21585240
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
7. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
Luque S; Grau S; Alvarez-Lerma F; Ferrández O; Campillo N; Horcajada JP; Basas M; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
[TBL] [Abstract][Full Text] [Related]
8. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies.
Lodise TP; Rhoney DH; Tam VH; McKinnon PS; Drusano GL
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):223-30. PubMed ID: 16423490
[TBL] [Abstract][Full Text] [Related]
10. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
[TBL] [Abstract][Full Text] [Related]
11. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
Cojutti P; Pai MP; Pea F
Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration.
Zheng J; Sun Z; Sun L; Zhang X; Hou G; Han Q; Li X; Liu G; Gao Y; Ye M; Wang H; Yu K
J Infect Dis; 2020 Mar; 221(Suppl 2):S279-S287. PubMed ID: 32176792
[TBL] [Abstract][Full Text] [Related]
14. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
[TBL] [Abstract][Full Text] [Related]
15. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers.
Cai Y; Bai N; Liu X; Liang B; Wang J; Wang R
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):765-71. PubMed ID: 26227096
[TBL] [Abstract][Full Text] [Related]
17. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.
Taubert M; Zander J; Frechen S; Scharf C; Frey L; Vogeser M; Fuhr U; Zoller M
J Antimicrob Chemother; 2017 Aug; 72(8):2304-2310. PubMed ID: 28541510
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment.
Barrasa H; Soraluce A; Isla A; Martín A; Maynar J; Canut A; Sánchez-Izquierdo JA; Rodríguez-Gascón A
J Crit Care; 2019 Apr; 50():69-76. PubMed ID: 30496913
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
